Andrei M, Nicolaie T, Stoicescu A, Teiușanu A, Gologan Ș, Diculescu M
Department of Gastroenterology, Hepatology and Digestive Endoscopy, Elias Emergency Hospital, Bucharest, Romania.
Department of Gastroenterology, Hepatology, Digestive Endoscopy, Fundeni Clinical Institute, Bucharest, Romania.
Curr Health Sci J. 2015 Jul-Sep;41(3):197-203. doi: 10.12865/CHSJ.41.03.01. Epub 2015 Jan 29.
IBD (inflammatory bowel diseases) represent chronic idiopathic inflammatory diseases, prone to relapse in the digestive tract; it is estimated that they result from the interaction of the intestinal microbiome with the intestinal immune system. The inflammatory microbiome exerts multiple beneficial roles. Perhaps the central element to developing IBD is dysbiosis; there is still an incompletely established association between intestinal microbiome changes in patients with IBD and SIBO (small intestinal bacterial overgrowth). Influencing the intestinal microbiome may play an adjuvant therapeutic role in the treatment of IBD. We present a synthesis of the connections between the entities mentioned above.
炎症性肠病（IBD）是一种慢性特发性炎症性疾病，易在消化道复发；据估计，它是由肠道微生物群与肠道免疫系统相互作用引起的。炎症性微生物群发挥着多种有益作用。也许IBD发病的核心因素是生态失调；IBD患者肠道微生物群变化与小肠细菌过度生长（SIBO）之间的关联仍未完全明确。影响肠道微生物群可能在IBD治疗中发挥辅助治疗作用。我们对上述各实体之间的联系进行了综述。
